Beam Therapeutics (BEAM) presented its pipeline updates at Citigroup's Biopharma Back to School Summit on September 9, 2026, as shares fell 6.17% in regular trading to $25.18 before recovering 1.21% after hours to $25.48. The stock was down 8.4% over the prior week, well below its 52-week high of $38.26 but above the 52-week low of $19.57.
The company stated it has a cash runway extending into mid-2029. Analyst price targets ranged from $26 to $80, with consensus implying strong-buy ratings and roughly 77% upside. Market capitalization stood at $2.54 billion, with a beta of 2.23 and current ratio of 14.57.
John Evans, Beam's chief executive officer, discussed the Risto-cel program for sickle cell disease, which is targeting the BEACON trial. A biologic license application is expected around the end of 2026, with a possible slip into early 2027. The addressable U.S. market is approximately 10,000 patients out of a total sickle cell population of about 100,000. Beam reported a 60/40 fetal hemoglobin to sickle hemoglobin ratio, complete resolution of anemia, and engraftment in roughly 16.5 days.
For BEAM-302, targeting alpha-1 antitrypsin deficiency, the first patient was dosed in July 2026. Levels reached the mid-teens—about 14 to 16 micromolar, within the protective MZ phenotype range—with approximately 93% M-AAT circulating and 7% Z-AAT, implying an 84% reduction in Z levels. A 50-patient pivotal cohort is currently enrolling across 14 sites in six countries. Beam said it is about two years ahead of its most advanced competitors in DNA editing for the indication. The addressable market includes roughly 100,000 ZZ genotype patients in the U.S., of whom about 10,000 to 15,000 are diagnosed and approximately 9,000 are on augmentation therapy, while up to 85,000 to 90,000 remain undiagnosed.
The BEAM-304 program for phenylketonuria (PKU), targeting the PAH gene, has an open IND with patient screening expected to start by late 2026. KUVAN and SEPHIENCE were noted as competitive products.
BEAM-301, targeting the R83C mutation in glycogen storage disease type 1A, is expected to report first-in-human data on a couple of dose cohorts in 2026.
Eric Foster, Beam's chief commercial officer, who previously worked at Ardelyx, also participated in the discussion. Citi senior biotech analyst Sam Semenkow moderated the session.
